Compare Cassava Sciences Inc (FLNA) vs Linde PLC (LIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Linde PLC — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Linde PLC trades at $482.59 (market cap $222.05B). The key difference: Linde PLC is far larger — about 5635.8× Cassava Sciences Inc's market cap, and Linde PLC pays a 1.33% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Linde PLC for 88 Days on average.
| FLNA | LIN | |
|---|---|---|
Market Cap | $39.40M | $222.05B |
Volume | 759,018 | 2,116,440 |
Sector | Health | Basic Materials |
52-Week High | $4.64 | $546.64 |
52-Week Low | $0.68 | $389.38 |
Typical Hold Time | 37 Days | 88 Days |
Enterprise Value | -$43.28M | $245.17B |
Dividend Yield | — | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
LIN trades at $481.70, down 1.68% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings of $4.50 per share, beating estimates, and raised the lower end of its 2026 guidance. Revenue growth is steady, with a net income margin of 20.43% in 2025. Analyst consensus is overwhelmingly positive, with a $557.10 price target. Support is seen near $480, while resistance lies at $486.
Outlook remains favorable due to consistent earnings beats and a record $8.1 billion project backlog. Risks include elevated valuation multiples and margin pressures from higher capital expenditures. The stock offers a dividend yield with a $1.60 payment scheduled for September 2026. Investor sentiment is buoyed by AI-related contract wins, though competition and capex increases warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
